Goldman Sachs raised Colon Pharmaceuticals's rating to buy, with a target price of 47 yuan.

Zhitongcaijing · 2d ago
Goldman Sachs raised Colon Pharmaceuticals's rating to buy, with a target price of 47 yuan.